Topline results show a 26% response rate in a Phase 2 clinical trial evaluating Ygalo (melflufen) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy’s developer, Oncopeptides, announced. These data will support a request for accelerated approval for Ygalo to treat people with triple-refractory multiple myeloma in the U.S., the...Continue Reading